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Drug Matrix cell D2: Organisational functioning: Generic and cross-cutting issues
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Chronic care for chronic conditions  (2002). Profound impl ications  of truly treating addiction of the kind seen by many treatment services  as  analogous to a
chronic disease. Also avai lable from this  source.
K  Organisational  health of Bri tish treatment services  (2009). Cl ients  engaged best when services  fostered communication, participation and trust among staff,
had a clear miss ion, but were open to new ideas. Organisational  health assessment tool  used in this  study has  been recommended for the UK. In the USA, feeding
back scores  from the tool  has  been found to motivate agencies  to improve.
K  Place your agency in front of a  potentia l ly unflattering mirror (2007). In the USA, feeding back scores  from the organisational  health scale used in a  Bri tish
study motivated less  wel l  functioning agencies  to commit to an improvement programme.
K  Organisational  correlates  of post-treatment drug use (2008). US study found that being constrained by funders  in terms of services  and abi l i ty to individual ise
treatments  was  the clearest negative factor, qual i ty accreditation the clearest pos itive.
K  Responsiveness  to patients ’ needs  associated with better outcomes (2010). Analys is  based on over 3000 US cl ients  found they stayed longer and did better at
services  which showed responsiveness  to need by offering help to get to treatment and organis ing the ‘wrap-around’ services  individuals  needed.
R  Pol icy strategies  for improving outcomes (2011). Two of the world’s  most respected addiction researchers  with top-level  pol icy experience explore the evidence
that patients ’ prospects  are improved by organisational  changes  l ike strengthening manageria l  capacity and bus iness  practices  and submitting the organisation
to external  scrutiny.
R  Organisational  dynamics  of the change process  (2011). US review structures  findings  from the most comprehensive and systematic attempt yet (see studies  1 2
from the same team) to map the processes  involved in effective treatment, including the organisational  dynamics  of implementing and sustaining innovations.
R  Implementing continuing care interventions  (2011). How to ensure patients  who need i t receive long-term care or aftercare.
G  Cl inical  governance in drug treatment ([UK] National  Treatment Agency for Substance Misuse, 2009). Guidance for providers  and commiss ioners .
G  QuADS Organisational  Standards  ([Irish] Health Service Executive and Ana Li ffey Drug Project, 2013). Checkl ist of practices  which consti tute qual i ty in
management, service del ivery, and service user rights , and for di fferent types  of services . The QuADS standards  were original ly developed for UK drug and alcohol
services; l inked document is  the update adopted by the Irish government.
G  Organisational  functioning and implementing improvements  ([UK] Substance Misuse Ski l l s  Consortium, accessed 2014). Col laboration of drug and alcohol
services  focused on workforce development offers  guidance and resources  relating to assess ing an agency’s  readiness  to change and the process  of introducing
new treatment interventions.
G  Implementing change ([US] Substance Abuse and Mental  Health Services  Administration, 2009). How to assess  an organisation’s  capacity to identi fy priori ties ,
implement changes, evaluate progress , and sustain effective programmes, and how to implement these programmes.
G  Theory into practice strategies  ([Austral ian] National  Centre for Education and Training on Addiction, 2005). Chapter on managing organisational  change
includes  the organisational  factors  which impede or promote change and how to manage them.
G  Five organisational  features  underlying successful  improvement programmes ([US] NIATx, accessed 2014). Web-based service supported by US government,
whose model  of organisational  improvement for addiction treatment services  is  based on five principles  such as  understanding and involving the customer and
seeking ideas  from other fields . Speci fic a ims include cutting waiting times and the number of ‘no-shows’, for which see cel l  C2.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and hot topic on why some treatment services  are more effective than others .
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What is this cell about? As well as concrete things like staff, management committees, resources, and an institutional structure,
organisations have links with other organisations, histories, values, priorities, and an ethos, determining whether they offer an
environment in which staff and patients/clients can maximise their potential. For these and other reasons, agencies differ in how keenly
and effectively they seek and incorporate knowledge and implement evidence-based practices. The best might, for example, have
effective procedures for monitoring performance and to identify when and what improvements are needed, facilitate staff learning from
research and from each other, and forge learning or service provision links with other organisations. Research cited in this cell is about
the impact of these attributes and about identifying and developing them. At this distance from the preoccupation with intervention
effectiveness, research is scarce, and generic sources (incorporated for example in Australian guidance) beyond the scope of the
matrices become more important.
Where should I start? Arguably no organisation has done more to promote evidence-based improvements in addiction treatment than
the US NIATx collaboration. The name recalls its initiation as the Network for the Improvement of Addiction Treatment. It has moved
beyond that but addiction remains a major focus. Study after study under the NIATx banner has examined how addiction treatment
organisations can become more receptive to improvements and more successfully implement them. The fruits of this work are freely
available on the NIATx web site.
Most relevant to this cell are the “five principles” found to have “consistently influenced efforts to overcome barriers to process
improvement”. Loosely based on findings from industry, these amount to a recipe for the kind of organisation which makes for successful
improvement. Listen (the video lasts just over eight minutes) to NIATx Director Dave Gustafson explain them. Note his stress on
organisations putting their staff in the customers’ shoes – not assuming they know what they need and want, but actively finding out. Ask
yourself, ‘What kind of organisation is that?’ – especially when its ‘customers’ are among the most stigmatised in society, ‘addicts’ by
definition incapable not just of doing, but even of really wanting what is best for them. The default position is surely to assume that as an
expert, and/or someone who has already extricated themselves from addiction, you know best.
One answer is that it is an organisation led by someone humble enough to think they can learn from such patients and who takes steps to
imbue that ethos across the service – the kind which from the late 1950s transformed intake and retention at the alcohol clinic of the
Massachusetts General Hospital. Part of that process was a proto ‘walk-through’ (see here for more on walk-throughs) of the intake
process to identify barriers from the patient’s point of view, now seen by NIATx as a key tactic.
Understanding and involving the customer is just one of NIATx’s five principles. Take a look at the others, see if to you they make sense,
and ask yourself if your organisation embodies these principles in its day to day work and its change efforts.
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Highlighted study Over decades of systematic research, Dwayne Simpson and colleagues at the US Institute of Behavioral Research
(visit web site for free assessment tools, manuals, and evidence-based advice on improving practice) developed a model of the treatment
process, and then moved on to assessing an organisation’s capacity to improve this process as reflected in staff perceptions of the
service and of their own professional functioning and needs. In 2006 study they teamed up with England’s National Treatment Agency for
Substance Misuse for the most wide-ranging investigation of the organisational health of British drug and alcohol treatment services ever
conducted. It found clear relationships between the micro level of the degree to which patients engaged with treatment, and macro
organisational features such as team working and mutual trust, whether the service fostered open communication between staff and was
receptive to staff ideas and concerns, was adequately resourced, and had a clear mission and programme. Like a more or less coherent,
well organised department store, all these and other features funnelled to a head in the interaction between staff and ‘customer’,
determining whether that customer wanted to stay and get sustainably better, or preferred to move on.
Issues to think about
 Should services gear up for long-term care/aftercare? If we believe addiction at least behaves like a chronic relapsing condition, and
even if that is only broadly valid for treatment populations, long-term care and/or monitoring would seem the appropriate treatment
strategy. In this cell you will find a review of how to ensure this happens. It argues that services must become “assertive” in linking
patients to continuing care if brief experiments in being drug-free (‘recovery initiation’) are to become sustained recovery maintenance.
That means, say the experts, forging close connections with external recovery support resources such as mutual aid groups, and seeing it
as a core part of your business to promote these to patients. Is this enough, or should the initial treatment service directly take
responsibility for extended monitoring and care (as seems indicated by this review). If they did, how would that square with the drive in
Britain to contain costs and maximise the numbers completing and leaving treatment (how services are increasingly called to account)?
Would diverting resources to extended care mean fewer patients get a chance of any kind of treatment?
Behind these questions are more fundamental ones about addiction and how drug treatment services should see themselves. The broad
cross section of drinkers who at some time become dependent can and commonly do extricate themselves with little or no formal help,
but cell A2’s bite argued that for drugs like heroin and cocaine, “By the time you have narrowed down to the minority who try these drugs,
the very few who become regular users, those of the former who become clinically dependent, and then the subset of those who want to
stop but can’t without treatment, then you have selected a highly atypical and usually multiply and deeply troubled population – the
caseload of addiction treatment services.”
For these people – especially those dependent on heroin with (for susceptible people) its distinctive
‘stickiness’ – perhaps services should see themselves as offering chronic care for a chronic condition. The
implication is that their performance should be judged on keeping the condition at bay while the patient is
under their care, rather than lasting post-treatment remission. According to this vision, post-treatment
relapse is a sign that treatment was working, not that it failed  chart. That was the view of the US expert
now advising Public Health England on addiction treatment. In turn he said that meant lengthy treatment
contact has to be palatable to and manageable by the patient, long-term monitoring of patients has to be a
recognised and funded part of treatment, and staff are needed to manage continuing care who like case
managers and GPs, are keyed in to the broader spectrum of health and social services.
 What makes a treatment service one which engages patients? At least since the mid-90s NTORS study in England reported its results, it
has been known that drug treatment services vary dramatically in their retention and outcomes, a common finding in studies of treatment
as it happens in normal practice outside a tightly controlled study. Exploring what accounts for that would take us way beyond addiction
in to organisational theories and findings from business, health services and the voluntary sector in general.
Let’s start more manageably with the Findings interpretation of this cell’s Highlighted study. It concluded: “Staff working in an
atmosphere of support and respect for their views, and concern for their development, tended to have clients who also felt understood,
respected, supported and helped ... also influential was the degree to which a service was clear about what it was trying to do and how it
was trying to do it, and communicated this to its staff.” Think of the services you know. Does this ring true? Look at the study and the
other studies in the Findings analysis. Are they strong enough to support these implications? After all, a service can have a “clear mission
and programme”, but both may be misguided. Perhaps the most important thing is not for an agency to understand, respect and support
staff, but to incentivise them to achieve/do what the agency wants them to achieve/do, whether or not they feel understood – like with
Scottish GPs incentivised to offer brief interventions. And/or, assuming the degree of caring to be expected of helping professionals,
more important is to let clinical staff know when patients are not doing well and suggest remedial action.
 Do we know how to make an organisation engaging and effective? The Highlighted study was about what kind of organisations are
naturally more effective. Can we use that and other studies to go a step further and actually engineer an effective organisation? The
obvious problem was highlighted by Australia’s internationally recognised addictions workforce development agency. It pointed out
(“First things first: Is a change needed?”) that first an organisation has to want to change – yet the very agencies most in need of change
may be the ones least likely to acknowledge this and to act on it.
One way to square this circle has been trialled by the US research stable responsible for the Highlighted study – alerting the service to
how its staff see it and how this compares with other services. Faced with the graphical evidence, senior staff from agencies which
scored as less open to change and staff suggestions were the ones most likely to commit to change.
Another way agencies can open themselves to an awareness of the need to change is to submit themselves for approval to accreditation
agencies, but this review from two of the world’s most respected addiction experts found this a weak lever for improving outcomes. More
promising are ‘walk-throughs’, when senior staff place themselves in the patients’ shoes (see Where should I start?), but would a poorly
functioning service consider such an exercise? Instead the US experts favoured engendering motivation for change by subjecting
agencies to market forces, of which in the UK the most prominent examples are payment by results schemes. Such schemes can force
change, but sometimes only that required to gain the externally imposed carrots and avoid the sticks.
We have described an apparent bind: Ideally health services and charities whose mission is to serve patients and clients will willingly
open themselves to influence and scrutiny and embrace improvements. But the ones doing least well in that mission are probably also
the ones least likely to take those steps. External pressure seems the solution, yet the same organisations may react by doing just what
is needed to satisfy their funders or inspectors rather than engaging in a sustained improvement programme focused not on external
requirements, but on the needs and aspirations of their actual and prospective patients. The market mechanism of patients voting with
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their feet is often not an option, and increasingly less so as mega-services take over in local areas, offering to do everything for the
commissioners. We will return to this issue from the point of view of commissioners in cell E2, and hope to find answers as well as
questions.
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